The Philippines’ Food and Drug Agency (FDA) issued circular 2012-007 on the regulation of clinical trials in the Philippines on June 7, recognizing DLSHSI as one of three Institutional Review Boards in the country to be endorsed and accredited by the Philippine Health Research and Ethics Board (PHREB) as regulatory review groups for clinical trials entering the country, especially phase 2 and 3 trials.


DLSHSI has taken up this important challenge to help assist FDA and be part of this private-public partnership. In its circular, the FDA cites the Philippines as the third fastest growing country in terms of clinical trial sites contributing to the global health research movement. Incidentally, DLSHSI’s VC for Mission and Linkages is also the current chair of the Philippine Clinical Research Infrastructure Network (PhilCriNet) an advisory body for clinical trials born of the Clinical Trials Summit and the Dasmariñas Declaration on Clinical Trials held at the De La Salle Villarosa Convention Hall in November 2011 as part of the De La Salle Centennial.